Determinants of interactions of a novel next-generation gabapentinoid NVA1309 and mirogabalin with the Cavα2δ-1 subunit

Simple item page
dc.contributor.authorSouza, Ivana A.
dc.contributor.authorGandini, Maria A.
dc.contributor.authorAli, Md Y.
dc.contributor.authorKricek, Franz
dc.contributor.authorSkouteris, George
dc.contributor.authorZamponi, Gerald W.
dc.date.accessioned2024-08-11T00:05:30Z
dc.date.available2024-08-11T00:05:30Z
dc.date.issued2024-08-07
dc.date.updated2024-08-11T00:05:30Z
dc.description.abstractAbstract NVA1309 is a non-brain penetrant next-generation gabapentinoid shown to bind Cavα2δ at R243 within a triple Arginine motif forming the binding site for gabapentin and pregabalin. In this study we have compared the effects of NVA1309 with Mirogabalin, a gabapentinoid drug with higher affinity for the voltage-gated calcium channel subunit Cavα2δ-1 than pregabalin which is approved for post-herpetic neuralgia in Japan, Korea and Taiwan. Both NVA1309 and mirogabalin inhibit Cav2.2 currents in vitro and decrease Cav2.2 plasma membrane expression with higher efficacy than pregabalin. Mutagenesis of the classical binding residue arginine R243 and the newly identified binding residue lysine K615 reverse the effect of mirogabalin on Cav2.2 current, but not that of NVA1309.
dc.identifier.citationMolecular Brain. 2024 Aug 07;17(1):54
dc.identifier.urihttps://doi.org/10.1186/s13041-024-01129-y
dc.identifier.urihttps://hdl.handle.net/1880/119387
dc.language.rfc3066en
dc.rights.holderThe Author(s)
dc.titleDeterminants of interactions of a novel next-generation gabapentinoid NVA1309 and mirogabalin with the Cavα2δ-1 subunit
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
13041_2024_Article_1129.pdf
Size:
2.51 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Open Access Publications